SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Repligen Corp (RGEN)
An SI Board Since February 1996
Posts SubjectMarks Bans Symbol
395 38 0 RGEN
Emcee:  Rajiv Hargunani Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
245Scott, How bullish are you on this one ? I am long from $5 and keep buying on Ace-10/6/2000
244<But I missed the therapy potential of chelation.> It's one of the maLLCF-9/30/2000
243David, Thanks. When I was at the third DAN! conference, one of the presentersScott H. Davis-9/30/2000
242More autism stuff.... plot thickening: cureautismnow.org CONCLUSION The historLLCF-9/28/2000
241just a heads up. haven't had time to look at this yet, but RGEN's entirscaram(o)uche-7/12/2000
240 <<I'll never understand why they aren't studying this instead [asScott H. Davis-6/10/2000
239 <the Autism Center will be established at the university's Center on HumLLCF-6/9/2000
238 UW receives $10 million to study autism A $5 million donation from a MicrosofCheryl Galt-6/9/2000
237 Repligen at Third Boston BioPharma Forum, June 5,2000-Live Ticker Company NamCurtis E. Bemis-5/31/2000
236 FYI, he is a parent with autistic children. He worked with the Autism ResearchScott H. Davis-5/23/2000
235 Richard, I like these guys too, and feel strongly that their research stands a Cheryl Galt-5/23/2000
234 Another "marker" for a pre-disposition to Autism is a very flawed andScott H. Davis-5/22/2000
233 Richard-- Thanx for your comments. I just think of the folks at Repligen, honCurtis E. Bemis-5/22/2000
232 Curtis: I coordinated one of biotech's first "deals" (human antiscaram(o)uche-5/22/2000
231 The story of CTLA4-Ig is a fascinating one. A young, bright biochemist friend Curtis E. Bemis-5/22/2000
230 Cheryl: No, not really. However, I feel, still, that RGEN's management isscaram(o)uche-5/22/2000
229 Rick, *thanks* for filling in so many details. I've wondered why U of M dCheryl Galt-5/22/2000
228 Cheryl: I haven't owned RGEN for ages, and therefore have not followed thescaram(o)uche-5/22/2000
227 Parking notes - some history of the CTLA4 patent dispute with BMS -------------Cheryl Galt-5/22/2000
226 Curtis, it looks like Repligen is side-stepping an impasse in its CTLA4 patent Cheryl Galt-5/22/2000
225 Repligen Acquires CTLA4 Patent Rights from Tolerance Therapeutics PR Newswire -Curtis E. Bemis-5/18/2000
224 New test for Autism Risk-- 4 proteins associated with brain development. RepliCurtis E. Bemis-5/4/2000
223 <the synthetic form for pancreatic diagnostics, is just an approval letter aLLCF-4/28/2000
222 Secretin-Repligen, the synthetic form for pancreatic diagnostics, is just an apCurtis E. Bemis-4/28/2000
221 Phase2 for autism, glad to see the patient ages here vs the other studies: WedLLCF-3/29/2000
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News